BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38549476)

  • 1. Evidence for external beam radiotherapy in mediastinal Hodgkin and non-Hodgkin lymphoma - systematic review.
    Kowalska M; Sitarz-Kilian E; Jaros K; Koperny M; Moćko P; Siwiec J; Kawalec P
    Ann Agric Environ Med; 2024 Mar; 31(1):47-56. PubMed ID: 38549476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.
    Franklin J; Eichenauer DA; Becker I; Monsef I; Engert A
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD008814. PubMed ID: 28901021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consolidative mediastinal irradiation of malignant lymphoma using active scanning proton beams: clinical outcome and dosimetric comparison.
    König L; Bougatf N; Hörner-Rieber J; Chaudhri N; Mielke T; Klüter S; Haefner MF; Rieken S; Haberer T; Debus J; Herfarth K
    Strahlenther Onkol; 2019 Jul; 195(7):677-687. PubMed ID: 30972453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy.
    Pinnix CC; Osborne EM; Chihara D; Lai P; Zhou S; Ramirez MM; Oki Y; Hagemeister FB; Rodriguez AM; Samaniego F; Fowler N; Romaguera JE; Turturro F; Fayad L; Westin JR; Nastoupil L; Neelapu SS; Cheah CY; Dabaja BS; Milgrom SA; Smith GL; Horace P; Milbourne A; Wogan CF; Ballas L; Fanale MA
    JAMA Oncol; 2016 Aug; 2(8):1065-9. PubMed ID: 27227654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma.
    Blank O; von Tresckow B; Monsef I; Specht L; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD007110. PubMed ID: 28447341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.
    Aldin A; Umlauff L; Estcourt LJ; Collins G; Moons KG; Engert A; Kobe C; von Tresckow B; Haque M; Foroutan F; Kreuzberger N; Trivella M; Skoetz N
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD012643. PubMed ID: 31525824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a phase 2 study.
    Hoppe BS; Flampouri S; Zaiden R; Slayton W; Sandler E; Ozdemir S; Dang NH; Lynch JW; Li Z; Morris CG; Mendenhall NP
    Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):1053-1059. PubMed ID: 24928256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.
    Aldin A; Umlauff L; Estcourt LJ; Collins G; Moons KG; Engert A; Kobe C; von Tresckow B; Haque M; Foroutan F; Kreuzberger N; Trivella M; Skoetz N
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012643. PubMed ID: 31930780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).
    Goldkuhle M; Dimaki M; Gartlehner G; Monsef I; Dahm P; Glossmann JP; Engert A; von Tresckow B; Skoetz N
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012556. PubMed ID: 30001476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
    Skoetz N; Will A; Monsef I; Brillant C; Engert A; von Tresckow B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD007941. PubMed ID: 28541603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton therapy in the management of non-Hodgkin lymphoma.
    Sachsman S; Flampouri S; Li Z; Lynch J; Mendenhall NP; Hoppe BS
    Leuk Lymphoma; 2015; 56(9):2608-12. PubMed ID: 25669925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma.
    Pinnix CC; Smith GL; Milgrom S; Osborne EM; Reddy JP; Akhtari M; Reed V; Arzu I; Allen PK; Wogan CF; Fanale MA; Oki Y; Turturro F; Romaguera J; Fayad L; Fowler N; Westin J; Nastoupil L; Hagemeister FB; Rodriguez MA; Ahmed S; Nieto Y; Dabaja B
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):175-82. PubMed ID: 25863764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does Radiation Have a Role in Advanced Stage Hodgkin's or Non-Hodgkin Lymphoma?
    Specht L
    Curr Treat Options Oncol; 2016 Jan; 17(1):4. PubMed ID: 26739151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualised Estimation of Quality-adjusted Survival Benefit and Cost-effectiveness of Proton Beam Therapy in Intermediate-stage Hodgkin Lymphoma.
    Jones DA; Candio P; Shakir R; Ramroth J; Wolstenholme J; Gray AM; Cutter DJ; Ntentas G
    Clin Oncol (R Coll Radiol); 2023 May; 35(5):301-310. PubMed ID: 36732121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
    Borchmann P; Plütschow A; Kobe C; Greil R; Meissner J; Topp MS; Ostermann H; Dierlamm J; Mohm J; Thiemer J; Sökler M; Kerkhoff A; Ahlborn M; Halbsguth TV; Martin S; Keller U; Balabanov S; Pabst T; Vogelhuber M; Hüttmann A; Wilhelm M; Zijlstra JM; Moccia A; Kuhnert G; Bröckelmann PJ; von Tresckow B; Fuchs M; Klimm B; Rosenwald A; Eich H; Baues C; Marnitz S; Hallek M; Diehl V; Dietlein M; Engert A
    Lancet Oncol; 2021 Feb; 22(2):223-234. PubMed ID: 33539742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotoxicity model-based patient selection for Hodgkin lymphoma proton therapy.
    Loap P; Orlandi E; De Marzi L; Vitolo V; Barcellini A; Iannalfi A; Dendale R; Kirova Y; Mirandola A
    Acta Oncol; 2022 Aug; 61(8):979-986. PubMed ID: 35668710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of radiation techniques in the treatment of mediastinal lymphoma: from 3D conformal radiotherapy (3DCRT) to intensity-modulated RT (IMRT) using helical tomotherapy (HT): a single-centre experience and review of the literature.
    Besson N; Pernin V; Zefkili S; Kirova YM
    Br J Radiol; 2016; 89(1059):20150409. PubMed ID: 26744079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma.
    Li J; Dabaja B; Reed V; Allen PK; Cai H; Amin MV; Garcia JA; Cox JD
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):167-74. PubMed ID: 20643518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vital organ sparing with proton therapy for pediatric Hodgkin lymphoma: Toxicity and outcomes in 50 patients.
    Tringale KR; Modlin LA; Sine K; Forlenza CJ; Cahlon O; Wolden SL
    Radiother Oncol; 2022 Mar; 168():46-52. PubMed ID: 35101461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.